Klinischer Einsatz von Heparinoiden

J. Harenberg; G. Huhle; L. Piazolo; D. L. Heene

doi:10.1055/s-0038-1656638

Hämostaseologie, Table of Contents

Hamostaseologie 1996; 16(01): 50-55
DOI: 10.1055/s-0038-1656638

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Klinischer Einsatz von Heparinoiden

J. Harenberg

¹1. Medizinische Klinik, Fakultät für klinische Medizin Mannheim der Universität Heidelberg (Direktor: Prof. Dr. med. D. L. Heene)

,

G. Huhle

¹1. Medizinische Klinik, Fakultät für klinische Medizin Mannheim der Universität Heidelberg (Direktor: Prof. Dr. med. D. L. Heene)

,

L. Piazolo

¹1. Medizinische Klinik, Fakultät für klinische Medizin Mannheim der Universität Heidelberg (Direktor: Prof. Dr. med. D. L. Heene)

,

D. L. Heene

¹1. Medizinische Klinik, Fakultät für klinische Medizin Mannheim der Universität Heidelberg (Direktor: Prof. Dr. med. D. L. Heene)

› Author Affiliations

Abstract

Zusammenfassung

Heparinoide werden seit nahezu 40 Jahren klinisch eingesetzt. Indikationsge-biete beruhen auf der entzündungshemmenden und antithrombotischen Wir-kung. Bei oraler Verabreichung steht die profibrinolytische Wirkung im Vordergrund. Für Dermatansulfat liegen pharmakokinetische Untersuchungen vor, die eine längere Halbwertszeit aufweisen im Vergleich zu Heparinen. Die Wirksamkeit bei der Hämodialyse 1st belegt. Das Heparinoid Org 10172 ist vielfältig unter-sucht. Seine Wirksamkeit in der postoperativen Thromboembolieprophylaxe und zur Thromboembolieprophylaxe bei Patienten mit Schlaganfall sowie die Wirk-samkeit in der Hämodialyse sind belegt. Eine erste Untersuchung zeigt eine Überlegenheit in der Therapie der frischen Venenthrombose im Vergleich zu unfraktioniertem Heparin. Als Alternative zur Weiterbehandlung bei Heparin-induzierter Thrombozytopenie ist diese Substanz wegweisend. Neue klinische Untersuchungen belegen somit die Wirksamkeit von Heparinoiden zur Prophylaxe und Therapie thromboembolischer Erkrankungen.

Keywords

Heparinoids - dermatansulfate - thromboembolism - prophylaxis - treatment

Full Text

References

LITERATUR
1 Dawes J, Hodson BA, MacGregor IR. et al. Pharmacokinetics and biological activities of dermatan sulphate (Mediolanum MF 701) in healthy human volunteers. Ann NY Acad Sci 1989; 556: 292-303
2 Dawes J, McLaren M, Forbes C. et al. The pharmacokinetics of dermatan sulphate MF701 in healthy volunteers. Br J Clin Pharmacol 1991; 32: 361-6
3 Dawes J. The pharmacokinetics of LMW dermatan sulphate: Long-term persistence of intact material. Thromb Haemost 1993; 69: 339-43
4 Dol F, Houin G, Rostin M. et al. Pharmacodynamics and pharmacokinetics of dermatan sulfate in humans. Blood 1989; 74: 1577-82
5 Dol F, Petitou M, Lormeau JC. et al. Pharmacologic properties of a low molecular weight dermatan sulphate: comparison with unfractionated dermatan sulphate. J Lab Clin Med 1990; 115: 43-51
6 Ofosu FA, Modi GJ, Smith LM. et al. Hepa-ransulphate and dermatan sulphate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984; 64: 742-7
7 Harenberg J, Jeschek M, Acker M. et al. Effects of low-molecular-weight dermatan-sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. Blood Coag Fibrinol (accepted for publication)
8 Danhof M, de Boer A, Magnani HN, Stiekema JCJ. Pharmacokinetic consideration on Orgaran (Org 10172) therapy. Haemostasis 1992; 22: 73-84
9 Cade JF, Wood M, Magnani HM, Westlake GW. Early clinical experience of a new heparinoid, Org 10172; in prevention of deep venous thrombosis. Thromb Res 1987; 45: 497-503
10 Hoek JA, Nurmohamed MT, Hamelynck KJ. et al. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992; 67: 28-32
11 Bergqvist D. Orgaran in hip fracture surgery. Haemostasis 1992; 22: 104-8
12 Bergqvist D, Kettunen K, Fredin H. et al. Thromboprophylaxis in patients with hip fractures: A prospective, randomized comparative study between Org 10172 and dextran 70. Surgery 1991; 109: 617-22
13 Gerhart TN, Yett HS, Robertzson LK. et al. Low-molecular-weight heparinoid compared with warfarin for prophylaxis of deep-vein thrombosis in patients who are operated on for fracture of the hip. A prospective, randomized trial. J Bone Joint Surg Am 1991; 73: 494-502
14 Leyvraz P, Bachmann F, Bohnet J. et al. Thromboembolic prophylaxis in total hip replacement: a comparison between the low molecular weight heparinoid Lomoparan and heparin-dihydroergotamine. Br J Surg 1992; 79: 911-4
15 Gallus A, Cade J, Ockelford P. et al. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomized, multicenter comparison. Thromb Haemost 1993; 562-7
16 Gallus A, Murphy W, Nacey J. et al. The influence of Org 10172; an antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy. Thromb Res 1989; 15: 229-38
17 ten Cate H, Henny P, ten Cate JW. et al. Randomized double-blind, placebo controlled safety study of a low molecular weight heparinoid in patients undergoing transurethral resection of the prostate. Thromb Haemost 1987; 57: 92-6
18 ten Cate H, Henny CP, Büller HR. et al. Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol 1984; 15: 268-70
19 Turpie AG, Levine MN, Hirsh J. et al. Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep vein thrombosis in thrombotic stroke. Lancet 1987; 1: 523-6
20 Turpie AGG, Gent M, Cote R. et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke. Ann Int Med 1992; 117: 353-7
21 Czechanowski B, Heinrich F. Prophylaxe venöser Thrombosen bei frischem ischämischem zerebrovaskulärem Insult - Dop-pelblind-Studie mit Heparin-Dihydergot. Dtsch Med Wochenschr 1981; 106: 1254-60
22 Adams HP, Woolson RF, Biller J, Clarke W. Studies of Org 10172 in patients with acute ischemic stroke. TOAST Study Group. Haemostasis 1992; 22: 99-103
23 Cofrancesco E, Boschetti C, Leonardi P. et al. Dermatan sulfate for the treatment of disseminated intravascular coagulation in acute leukemia: a randomised, heparin-con-trolled pilot study. Thromb Res 1994; 74: 65-75
24 Nieuwenhuis HK, Sixma JJ. Treatment of disseminated intravascular coagulation in acute promyelocytic leukemia with low molecular weight heparinoid Org 10172. Cancer 1986; 58: 761-4
25 Ryan KE, Lane DA, Flynn A. et al. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Thromb Haemost 1992; 68: 563-9
26 Von Bonsdorff M, Stiekema J, Harjanne A, Alapiessa U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int J Artif Org 1990; 13: 103-8
27 Henny CP, ten Cate H, Surachno S. et al. The effectiveness of a low molecular weight heparinoid in chronic intermittent haemodialysis. Thromb Haemost 1985; 54: 460-2
28 Ireland H, Lane DA, Flynn A. et al. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: An objective assessment. Thromb Haemost 1986; 55: 271-5
29 Henny HP, ten Cate H, ten Cate JW. et al. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs. J Lab Clin Med 1985; 106: 187-96
30 Henny CP, ten Cate H, ten Cate JW. et al. Use of a new heparinoid as anticoagulant during acute haemodialysis of patients with bleeding complications. Lancet 1983; 1: 890-3
31 de Valk HW, Banga JD, Wester JW. et al. Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial. Ann Int Med 1995; 123: 1-9
32 Berrazueta JR, Poveda JJ, Ochoteco J. et al. The anti-inflammatory and analgesic action of transdermal glycerylnitrate in the treatment of infusion-related thrombophlebitis. Postgrad Med J 1993; 69: 37-40
33 Ruland WO, Schwering L, Steffen W, Muhl-schlegel A. Soft tissue swelling in sports traumatology. Comparative study of the effectiveness of 2 ointments. Aktuel Traumatol 1991; 21: 24-7
34 Dragani L, Giamberardino MA, D'Aurelio A. et al. Evaluation of reduction of NSAID comsumption after local treatment with a heparin-heparinoid combination in patients with osteoarthritis. Riv Eur Sci Med Farma-col 1990; 12: 283-95
35 Sindet-Pedersen S, Lund E, Simonsen EK, Stenbjerg S. The anti-inflammatory effect of organo-heparinoid cream after bilateral mandibular osteotomies. Int J Oral Maxillo-fax Surg 1989; 18: 35-8
36 Harenberg J, Böhme J, Stehle G, Heene DL. Resorption subkutaner Hämatome. Klinikarzt 1993; 22: 297-301
37 Harenberg J, Böhme J, Wolf H. Resorption subkutaner Hämatome unter niedermolekularem Heparin mit und ohne Penetrationsvermittler (Publikation in Vorbereitung).
38 Ambrosio LA, Marchese G, Filippo A. et al. The effect of mesoglycan in patients with cerebrovascular disease: a psychometric evaluation. J Int Med Res 1993; 21: 138-46
39 Ban TA, Morey LC, Fjetland OK. et al. Early manifestations of dementing illness: treatment with glycosaminoglycan poly-sulfate. Prog Neurophsychopharmacol Biol Psychiatry 1992; 16: 661-76
40 Passeri M, Cucinotta D. Ateroid in the clinical treatment of multi-infarct dementia. Mod Probl Pharmacopsychiatry 1989; 23: 85-94
41 Hari PR, Sharma CP. Grafting of synthetic polyelectrolyte onto polymer surfaces -comparison of glow discharge and 60Co-gamma-irradiation method. J Biomater Appl 1990; 5: 20-6
42 Ito Y, Imanishi Y. Non-thrombogenicity by novel surface modification methods. J Biomater Appl 1992; 6: 293-318
43 Ito Y, Iguchi Y, Imanishi Y. Synthesis and non-thrombogenicity of heparinoid poly-urethaneureas. Biomaterials 1992; 13: 131-5